Speech-Language Pathologists in Barre, VT Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Mrs. Judith Carol Yandow, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20 Clifton Street, Barre, VT 05641 Phone: 802-479-7039 |
Mrs. Shannon Planck Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 378 Prospect St, Barre, VT 05641 Phone: 802-476-4166 |
Patricia S Taffel, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 64 West Rd, Barre, VT 05641 Phone: 802-479-2109 |
Miss Kristy Lyn Antonacci, M.S., CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 98 Hospitality Dr, Barre, VT 05641 Phone: 802-229-0308 |
News Archive
NIMH-funded project aims to identify genetic causes of schizophrenia
Researchers at the University of Virginia School of Medicine will seek to identify the genetic causes of schizophrenia as part of a major project funded by the National Institute of Mental Health to better understand how genetic variation in brain cells affects human health and disease.
Sudden cardiac arrest survivors to gather at SCAA Annual Meeting
A nationwide gathering of sudden cardiac arrest (SCA) survivors, emergency responders and civilian rescuers will mark SCA Awareness Month with a Survivors & Heroes Celebration on Friday, October 8 at 6:00 p.m. at the Marriott City Center in Pittsburgh, Pennsylvania.
Today's Opinions: Prevention and small business; Views on medical inflation and health reform; Sebelius letter examined
In this anemic economy, small businesses need all the help they can get, and the Prevention and Public Health Fund provides the best medicine (Dr. Georges Benjamin and Larry Cohen, 9/13).
Researchers identify bio-markers that could help detect early stage colorectal cancer
Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU Leuven - together with various European oncology centers, including UZ Leuven - have identified bio-markers that can be incorporated in a new diagnostic test.
New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastases
New Phase II data suggests that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.
› Verified 4 days ago
Physical Therapists
Occupational Therapists
Chiropractors
Speech-Language Pathologists
Optometrists